Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Singh, RP, Wykoff, CC, Brown, DM, Larsen, M, Terasaki, H, Silva, FQ, Saroj, N, Gibson, A, Vitti, R, Kayshap, S, Berliner, AJ, Zeitz, O, Metzig, C, Thompson, D & Nguyen, QD 2017, 'Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID', Ophthalmology Retina, vol. 1, no. 5, pp. 382-388. https://doi.org/10.1016/j.oret.2017.02.003

APA

Singh, R. P., Wykoff, C. C., Brown, D. M., Larsen, M., Terasaki, H., Silva, F. Q., Saroj, N., Gibson, A., Vitti, R., Kayshap, S., Berliner, A. J., Zeitz, O., Metzig, C., Thompson, D., & Nguyen, Q. D. (2017). Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID. Ophthalmology Retina, 1(5), 382-388. https://doi.org/10.1016/j.oret.2017.02.003

CBE

Singh RP, Wykoff CC, Brown DM, Larsen M, Terasaki H, Silva FQ, Saroj N, Gibson A, Vitti R, Kayshap S, Berliner AJ, Zeitz O, Metzig C, Thompson D, Nguyen QD. 2017. Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID. Ophthalmology Retina. 1(5):382-388. https://doi.org/10.1016/j.oret.2017.02.003

MLA

Vancouver

Author

Singh, Rishi P. ; Wykoff, Charles C. ; Brown, David M. ; Larsen, Michael ; Terasaki, Hiroko ; Silva, Fabiana Q. ; Saroj, Namrata ; Gibson, Andrea ; Vitti, Robert ; Kayshap, Sangeeta ; Berliner, Alyson J. ; Zeitz, Oliver ; Metzig, Carola ; Thompson, Desmond ; Nguyen, Quan Dong. / Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c : Analyses from VISTA and VIVID. In: Ophthalmology Retina. 2017 ; Vol. 1, No. 5. pp. 382-388.

Bibtex

@article{2143f88441804c58a8c2f3d6ee02fe2b,
title = "Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID",
abstract = "Purpose To examine the relationship between glycemic control at baseline and response to anti–vascular endothelial growth factor treatment for diabetic macular edema (DME). Design Post hoc analysis of 2 similarly designed phase III trials, VISTA and VIVID. Participants Patients with central-involved DME. Methods Both VISTA and VIVID compared efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for DME. Current analysis focused on comparison within each treatment group in an integrated VISTA and VIVID dataset. Baseline hemoglobin A1c (HbA1c) was partitioned into 4 quartiles: 4.5% to <6.7% (n = 233), 6.7% to <7.4% (n = 206), 7.4% to <8.6% (n = 209), and 8.6% to <14.7% (n = 208). Outcomes were analyzed by mixed model for repeated measures. Intragroup differences were quantified by a regression model. Main Outcome Measures Change from baseline best-corrected visual acuity (BCVA), central subfield thickness (CST), and HbA1c. Results In the IAI group, mean BCVA improvement from baseline did not depend on baseline HbA1c at week 52 (P = 0.1852), but seemed to be dependent at week 100 (P = 0.0425). The mean CST reduction from baseline was independent of baseline HbA1c at both weeks 52 (P = 0.1857) and 100 (P = 0.7346). Mean HbA1c change from baseline in IAI group was small across all HbA1c quartiles. In the laser group, the mean BCVA gain decreased with increasing baseline HbA1c at both weeks 52 (P = 0.0421) and 100 (P = 0.0001). Similarly, the mean CST decrease was greater with decreasing baseline HbA1c, at both weeks 52 (P = 0.0065) and 100 (P = 0.0162). The mean HbA1c change from baseline in the laser group was minimal across HbA1c quartiles, although glycemic control tended to worsen in upper quartiles. Conclusions The benefit of IAI in patients with DME was less dependent on their presenting glycemic status as opposed to laser.",
author = "Singh, {Rishi P.} and Wykoff, {Charles C.} and Brown, {David M.} and Michael Larsen and Hiroko Terasaki and Silva, {Fabiana Q.} and Namrata Saroj and Andrea Gibson and Robert Vitti and Sangeeta Kayshap and Berliner, {Alyson J.} and Oliver Zeitz and Carola Metzig and Desmond Thompson and Nguyen, {Quan Dong}",
year = "2017",
month = sep,
day = "1",
doi = "10.1016/j.oret.2017.02.003",
language = "English",
volume = "1",
pages = "382--388",
journal = "Ophthalmology Retina",
issn = "2468-7219",
publisher = "Elsevier Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c

T2 - Analyses from VISTA and VIVID

AU - Singh, Rishi P.

AU - Wykoff, Charles C.

AU - Brown, David M.

AU - Larsen, Michael

AU - Terasaki, Hiroko

AU - Silva, Fabiana Q.

AU - Saroj, Namrata

AU - Gibson, Andrea

AU - Vitti, Robert

AU - Kayshap, Sangeeta

AU - Berliner, Alyson J.

AU - Zeitz, Oliver

AU - Metzig, Carola

AU - Thompson, Desmond

AU - Nguyen, Quan Dong

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose To examine the relationship between glycemic control at baseline and response to anti–vascular endothelial growth factor treatment for diabetic macular edema (DME). Design Post hoc analysis of 2 similarly designed phase III trials, VISTA and VIVID. Participants Patients with central-involved DME. Methods Both VISTA and VIVID compared efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for DME. Current analysis focused on comparison within each treatment group in an integrated VISTA and VIVID dataset. Baseline hemoglobin A1c (HbA1c) was partitioned into 4 quartiles: 4.5% to <6.7% (n = 233), 6.7% to <7.4% (n = 206), 7.4% to <8.6% (n = 209), and 8.6% to <14.7% (n = 208). Outcomes were analyzed by mixed model for repeated measures. Intragroup differences were quantified by a regression model. Main Outcome Measures Change from baseline best-corrected visual acuity (BCVA), central subfield thickness (CST), and HbA1c. Results In the IAI group, mean BCVA improvement from baseline did not depend on baseline HbA1c at week 52 (P = 0.1852), but seemed to be dependent at week 100 (P = 0.0425). The mean CST reduction from baseline was independent of baseline HbA1c at both weeks 52 (P = 0.1857) and 100 (P = 0.7346). Mean HbA1c change from baseline in IAI group was small across all HbA1c quartiles. In the laser group, the mean BCVA gain decreased with increasing baseline HbA1c at both weeks 52 (P = 0.0421) and 100 (P = 0.0001). Similarly, the mean CST decrease was greater with decreasing baseline HbA1c, at both weeks 52 (P = 0.0065) and 100 (P = 0.0162). The mean HbA1c change from baseline in the laser group was minimal across HbA1c quartiles, although glycemic control tended to worsen in upper quartiles. Conclusions The benefit of IAI in patients with DME was less dependent on their presenting glycemic status as opposed to laser.

AB - Purpose To examine the relationship between glycemic control at baseline and response to anti–vascular endothelial growth factor treatment for diabetic macular edema (DME). Design Post hoc analysis of 2 similarly designed phase III trials, VISTA and VIVID. Participants Patients with central-involved DME. Methods Both VISTA and VIVID compared efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for DME. Current analysis focused on comparison within each treatment group in an integrated VISTA and VIVID dataset. Baseline hemoglobin A1c (HbA1c) was partitioned into 4 quartiles: 4.5% to <6.7% (n = 233), 6.7% to <7.4% (n = 206), 7.4% to <8.6% (n = 209), and 8.6% to <14.7% (n = 208). Outcomes were analyzed by mixed model for repeated measures. Intragroup differences were quantified by a regression model. Main Outcome Measures Change from baseline best-corrected visual acuity (BCVA), central subfield thickness (CST), and HbA1c. Results In the IAI group, mean BCVA improvement from baseline did not depend on baseline HbA1c at week 52 (P = 0.1852), but seemed to be dependent at week 100 (P = 0.0425). The mean CST reduction from baseline was independent of baseline HbA1c at both weeks 52 (P = 0.1857) and 100 (P = 0.7346). Mean HbA1c change from baseline in IAI group was small across all HbA1c quartiles. In the laser group, the mean BCVA gain decreased with increasing baseline HbA1c at both weeks 52 (P = 0.0421) and 100 (P = 0.0001). Similarly, the mean CST decrease was greater with decreasing baseline HbA1c, at both weeks 52 (P = 0.0065) and 100 (P = 0.0162). The mean HbA1c change from baseline in the laser group was minimal across HbA1c quartiles, although glycemic control tended to worsen in upper quartiles. Conclusions The benefit of IAI in patients with DME was less dependent on their presenting glycemic status as opposed to laser.

UR - http://www.scopus.com/inward/record.url?scp=85038439694&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2017.02.003

DO - 10.1016/j.oret.2017.02.003

M3 - Journal article

AN - SCOPUS:85038439694

VL - 1

SP - 382

EP - 388

JO - Ophthalmology Retina

JF - Ophthalmology Retina

SN - 2468-7219

IS - 5

ER -

ID: 59452120